NeuroBo Pharmaceuticals Statistics
Share Statistics
NeuroBo Pharmaceuticals has 8.62M shares outstanding. The number of shares has increased by 74.93% in one year.
| Shares Outstanding | 8.62M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 49.7% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.10M |
| Failed to Deliver (FTD) Shares | 2.69K |
| FTD / Avg. Volume | 5.99% |
Short Selling Information
The latest short interest is 19.20K, so 0.22% of the outstanding shares have been sold short.
| Short Interest | 19.20K |
| Short % of Shares Out | 0.22% |
| Short % of Float | 0.64% |
| Short Ratio (days to cover) | 0.38 |
Valuation Ratios
The PE ratio is -1.5 and the forward PE ratio is -1.51.
| PE Ratio | -1.5 |
| Forward PE | -1.51 |
| PS Ratio | 0 |
| Forward PS | 2904.8 |
| PB Ratio | 1.12 |
| P/FCF Ratio | -1.73 |
| PEG Ratio | n/a |
Enterprise Valuation
NeuroBo Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.78, with a Debt / Equity ratio of 0.
| Current Ratio | 3.78 |
| Quick Ratio | 3.78 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.4 |
| Cash Flow / Debt | -161.18 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.75% and return on capital (ROIC) is -94.07%.
| Return on Equity (ROE) | -0.75% |
| Return on Assets (ROA) | -0.55% |
| Return on Capital (ROIC) | -94.07% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.56M |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -39.8% in the last 52 weeks. The beta is -0.28, so NeuroBo Pharmaceuticals 's price volatility has been lower than the market average.
| Beta | -0.28 |
| 52-Week Price Change | -39.8% |
| 50-Day Moving Average | 2.73 |
| 200-Day Moving Average | 3.81 |
| Relative Strength Index (RSI) | 40.85 |
| Average Volume (20 Days) | 45.00K |
Income Statement
In the last 12 months, NeuroBo Pharmaceuticals had revenue of $0 and earned -$12.47M in profits. Earnings per share was $-2.46.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -15.89M |
| Net Income | -12.47M |
| EBITDA | -15.88M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.46 |
Balance Sheet
The company has $22.43M in cash and $203.00K in debt, giving a net cash position of $22.23M.
| Cash & Cash Equivalents | 22.43M |
| Total Debt | 203.00K |
| Net Cash | 22.23M |
| Retained Earnings | -108.27M |
| Total Assets | 22.15M |
| Working Capital | 12.82M |
Cash Flow
In the last 12 months, operating cash flow was -$10.80M and capital expenditures -$50.00K, giving a free cash flow of -$10.85M.
| Operating Cash Flow | -10.80M |
| Capital Expenditures | -50.00K |
| Free Cash Flow | -10.85M |
| FCF Per Share | -2.14 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
NRBO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -104.24% |
| FCF Yield | -53.35% |
Analyst Forecast
The average price target for NRBO is $10, which is 323.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 323.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 21, 2023. It was a backward split with a ratio of 1:8.
| Last Split Date | Dec 21, 2023 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | -10.06 |
| Piotroski F-Score | 2 |